A pill a day: testing a new shield against HIV for women
NCT ID NCT03058835
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looks at whether US women at risk for HIV can and will take Truvada, a daily pill that prevents HIV infection. Researchers will measure how well women stick to the pill regimen over 24 weeks and explore their attitudes toward this prevention method. The goal is to see if this approach is practical and acceptable for women in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Truvada (tenofovir disoproxil and emtricitabine) tablets taken daily as pre-exposure prophylaxis
- What this could lead to
- If successful, this could show that daily PrEP is a practical and acceptable way to reduce HIV risk in US women, potentially expanding its use.
- What could go wrong
- This is a demonstration project, not a large efficacy trial, so results may not apply broadly. Adherence may be lower than hoped, and side effects or access barriers could limit real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREP ADHERENCE MONITORING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
New Jersey Medical School Clinical Research Center
Newark, New Jersey, 07103, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
West Virginia University
Morgantown, West Virginia, 26505, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.